Physician profile
Peter E Cestodio
NPI 1780373886
$2,431.90
in general payments reported to CMS, 2019-2025
21 companies · $968 in 2025
The $968 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $190 · 2024: $1,273 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,317 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.56 |
| Education | $115.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $613.29 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $542.18 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $158.86 | 2024-2025 | Vowst |
| Lilly USA, LLC | $136.67 | 2023-2025 | Omvoh, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $130.98 | 2024-2025 | Entyvio |
| Ardelyx, INC. | $104.60 | 2024-2025 | Ibsrela |
| Celgene Corporation | $96.40 | 2024 | Zeposia |
| Gilead Sciences, INC. | $85.54 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $76.57 | 2024-2025 | Dupixent |
| Pfizer INC. | $69.32 | 2023-2025 | |
| Qol Medical, LLC | $68.82 | 2025 | Sucraid |
| Organon LLC | $63.89 | 2023-2024 | Hadlima, Renflexis |
| Phathom Pharmaceuticals, INC. | $56.49 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $39.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sandoz INC. | $35.22 | 2023 | Hyrimoz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $32.32 | 2024 | |
| Fresenius Kabi USA, LLC | $28.18 | 2024 | Idacio |
| Ipsen Biopharmaceuticals, INC | $26.07 | 2024 | Iqirvo |
| Merck Sharp & Dohme LLC | $23.33 | 2023 | Dificid |
| Madrigal Pharmaceuticals | $22.88 | 2025 | Rezdiffra |
| Celltrion USA INC. | $20.70 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Cestodio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.